Related Experiment Video

Updated: Feb 21, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.8K

Association between kidney function and genetic polymorphisms in atherosclerotic and chronic kidney diseases: A

Yoko Kubo1, Takahiro Imaizumi2, Masahiko Ando1

  • 1Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.

Plos One
|October 11, 2017
PubMed

Insights

This study identifies specific genetic markers, BRAP rs3782886 and SPATA5L1 rs2467853, associated with chronic kidney disease (CKD) risk. A developed genetic risk score (GRS) also shows a significant link to CKD development.

Area of Science:

  • Genetics
  • Nephrology
  • Cardiovascular Disease

Background:

  • Single nucleotide polymorphisms (SNPs) are linked to chronic kidney disease (CKD) predisposition.
  • The role of atherosclerosis-related SNPs in CKD incidence requires further investigation.

Purpose of the Study:

  • To identify SNPs associated with CKD.
  • To determine if accumulated risk alleles contribute to CKD development.

Main Methods:

  • A cross-sectional study analyzed 4814 male workers, examining estimated glomerular filtration rate (eGFR) and 59 candidate polymorphisms.
  • A genetic risk score (GRS) was calculated based on significant risk alleles.
  • Multivariate logistic regression, ROC curve analysis, IDI, and cNRI were employed.

Main Results:

  • Eight candidate SNPs showed association with eGFR (P < 0.05) after adjustment.
  • BRAP rs3782886 and SPATA5L1 rs2467853 were significantly associated with eGFR (FDR < 0.05).
  • The GRS was significantly associated with CKD (OR, 1.17; 95% CI, 1.09-1.26), improving IDI and cNRI.

Conclusions:

  • Kidney function is associated with BRAP rs3782886 and SPATA5L1 rs2467853.
  • The developed GRS for CKD demonstrated a significant association with CKD after clinical factor adjustment.
Abstract

More Related Videos

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format05:58

Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format

Published on: August 20, 2018

11.5K
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

22.2K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
20
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
25
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
27
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
27
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
23
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.8K